Immunomedics, Inc. (IMMU) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $12.38, down from yesterday’s close by -8.50%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.
Does this stock stack up well when compared to its peers in the industry space? Let’s take a look. Immunomedics, Inc. (IMMU) currently trades with a market capitalization of $1.52 Billion.
The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For IMMU, the company currently has $43.39 Million of cash on the books. You can get a sense of how sustainable that is by a levered free cash flow of $-64.09 Million over the past twelve months. Generally speaking, earnings are expected to fall in coming quarters. Analysts are forecasting earnings of $-0.11 on a per share basis this quarter. Perhaps, that suggests something about why 71.01% of the outstanding share supply is held by institutional investors.
Sometimes, we can understand most about a stock by simply looking at how it has been trading. Looking at the stock’s movement on the chart, Immunomedics, Inc. recorded a 52-week high of $14.48. It is now trading 2.1% off that level. The stock is trading $10.64 its 50-day moving average by -1.74%. The stock carved out a 52-week low down at $2.02.
In recent action, Immunomedics, Inc. (IMMU) has made a move of +3.95% over the past month, which has come on weak relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 17.45, and it’s gotten there by action that has been more volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 29.81% with $116.13 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of IMMU.